Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
21 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Délais de RDV courts dans la région
78.3 rhumatos / 100 000 hab. — département bien doté
5ans d'exercice (thèse 2021)
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
31
31 articles ont été cités au moins 31fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
5 282
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
247
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
63
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris-Saclay · Université Sorbonne Paris Nord · Hôpital Avicenne
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Tracheobronchial Replacement Using Cryopreserved Aortic Allografts: Results in 50 Patients (TRITON-01 Registry)
2026ArticleEuropean Journal of Cardio-Thoracic Surgery
Regulatory T Cells Poise the Myeloid Landscape after Chemotherapy in Lung Tumors
2025ArticleCancer Immunology Research
Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2024ArticleGenome Medicine
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2023ArticleGenome Medicine
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8 + T cells in patients with advanced NSCLC
2023ArticleScience Advances
ICU admission for solid cancer patients treated with immune checkpoint inhibitors
2023ArticleAnnals of Intensive Care
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy
2023ArticleCancers
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
2023ArticleTherapeutic Advances in Medical Oncology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP HU PSSD SITE AVICENNE
125 R DE STALINGRAD, 93009 BOBIGNY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Cancer immunology, immunotherapy : CII · 2022
Frontiers in medicine · 2023
Diagnosing pulmonary sarcoidosis raises challenges due to both the absence of a specific diagnostic criterion and the varied presentations capable of mimicking many other conditions. The aim of this review is to help non-sarcoidosis experts establish optimal differential-diagnosis strategies tailored to each situation. Alternative granulomatous diseases that must be ruled out include infections (notably tuberculosis, nontuberculous mycobacterial infections, and histoplasmosis), chronic beryllium disease, hypersensitivity pneumonitis, granulomatous talcosis, drug-induced granulomatosis (notably due to TNF-a antagonists, immune checkpoint inhibitors, targeted therapies, and interferons), immune deficiencies, genetic disorders (Blau syndrome), Crohn’s disease, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and malignancy-associated granulomatosis. Ruling out lymphoproliferative disorders may also be very challenging before obtaining typical biopsy specimen. The first step is an assessment of epidemiological factors, notably the incidence of sarcoidosis and of alternative diagnoses; exposure to risk factors (e.g., infectious, occupational, and environmental agents); and exposure to drugs taken for therapeutic or recreational purposes. The clinical history, physical examination and, above all, chest computed tomography indicate which differential diagnoses are most likely, thereby guiding the choice of subsequent investigations (e.g., microbiological investigations, lymphocyte proliferation tests with metals, autoantibody assays, and genetic tests). The goal is to rule out all diagnoses other than sarcoidosis that are consistent with the clinical situation. Chest computed tomography findings, from common to rare and from typical to atypical, are described for sarcoidosis and the alternatives. The pathology of granulomas and associated lesions is discussed and diagnostically helpful stains specified. In some patients, the definite diagnosis may require the continuous gathering of information during follow-up. Diseases that often closely mimic sarcoidosis include chronic beryllium disease and drug-induced granulomatosis. Tuberculosis rarely resembles sarcoidosis but is a leading differential diagnosis in regions of high tuberculosis endemicity.
Frontiers in oncology · 2023
PurposeRadiation-induced lung injury (RILI) is strongly associated with various clinical conditions and dosimetric parameters. Former studies have led to reducing radiotherapy (RT) doses to the lung and have favored the discontinuation of tamoxifen during RT. However, the monocentric design and variability of dosimetric parameters chosen have limited further improvement. The aim of our study was to assess the incidence of RILI in current practice and to determine clinical and dosimetric risk factors associated with RILI occurrence.Material and methodsData from 3 out of the 10 top recruiting centers in CANTO-RT, a subset of the CANTO prospective longitudinal cohort (NCT01993498), were retrospectively analyzed for RILI occurrence. This cohort, which recruited invasive cT0-3 cN0-3 M0 breast cancer patients from 2012 to 2018, prospectively recorded the occurrence of adverse events by questionnaires and medical visits at the end of, and up to 60 months after treatment. RILI adverse events were defined in all patients by the association of clinical symptoms and compatible medical imaging.ResultsRILI was found in 38/1565 (2.4%) patients. Grade II RILI represented 15/38 events (39%) and grade III or IV 2/38 events (6%). There were no grade V events. The most frequently used technique for treatment was 3D conformational RT (96%). In univariable analyses, we confirmed the association of RILI occurrence with pulmonary medical history, absence of cardiovascular disease medical history, high pT and pN, chemotherapy use, nodal RT. All dosimetric parameters were highly correlated and had close predictive value. In the multivariable analysis adjusted for chemotherapy use and nodal involvement, pulmonary medical history (OR=3.05, p<0.01) and high V30 Gy (OR=1.06, p=0.04) remained statistically significant risk factors for RILI occurrence. V30 Gy >15% was significantly associated with RILI occurrence in a multivariable analysis (OR=3.07, p=0.03).ConclusionOur study confirms the pulmonary safety of breast 3D RT in CANTO-RT. Further analyses with modern radiation therapy techniques such as IMRT are needed. Our results argue in favor of a dose constraint to the ipsilateral lung using V30 Gy not exceeding 15%, especially in patients presenting pulmonary medical history. Pulmonary disease records should be taken into account for RT planning.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Breathe (Sheffield, England) · 2024 · Journal Article
Mayenga M, Pedroso AR, Ferreira M, Gille T, et al.
Bulletin du cancer · 2024 · Letter
Crenier R, Duchemann B
Respiratory medicine and research · 2023 · Journal Article
Lasvergnas J, Fallet V, Duchemann B, Jouveshomme S, et al.
Bulletin du cancer · 2023 · English Abstract
Teixeira L, Diéras V, Crestani B, Lederlin M, et al.
Bulletin du cancer · 2021 · News
Chevassut D, Duchemann B
Infectious diseases (London, England) · 2021 · Journal Article
Comparon C, Boubaya M, Sritharan N, Dournon N, et al.
Respiratory medicine and research · 2025 · Letter
Naulleau G, Matton L, Hutuca I, Fremand X, et al.
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2022 · Case Reports
Duchemann B, Portela AM, Joudiou P, Freynet O, et al.
Frontiers in oncology · 2022 · Case Reports
Wang P, Fabre E, Martin A, Chouahnia K, et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026 · Journal Article
Martinod E, Onorati I, Radu DM, Santos Portela AM, et al.
Frontiers in oncology · 2023 · Journal Article
Gueiderikh A, Sarrade T, Kirova Y, De La Lande B, et al.
Thoracic cancer · 2023 · Journal Article
Lambert T, El Husseini K, Zysman M, Duchemann B, et al.
Nature medicine · 2026 · Journal Article
Huang Z, Zeng L, Ruan Z, Zeng Q, et al.
European journal of cancer (Oxford, England : 1990) · 2025 · Clinical Trial, Phase II
Menis J, Greiller L, Demontrond P, Monnet I, et al.
Cancer immunology, immunotherapy : CII · 2022 · Journal Article
Landre T, Justeau G, Assié JB, Chouahnia K, et al.
JAMA surgery · 2025 · Journal Article
Martinod E, Radu DM, Onorati I, Chapalain X, et al.
Cancer immunology, immunotherapy : CII · 2022 · Journal Article
Landre T, Justeau G, Assié JB, Chouahnia K, et al.
JAMA surgery · 2025 · Journal Article
Martinod E, Radu DM, Onorati I, Chapalain X, et al.
Frontiers in medicine · 2023 · Journal Article
Valeyre D, Brauner M, Bernaudin JF, Carbonnelle E, et al.
Lung cancer (Amsterdam, Netherlands) · 2025 · Journal Article
Pierret T, Greillier L, Guisier F, Daniel C, et al.
Therapeutic advances in medical oncology · 2023 · Journal Article
Assié JB, Chouaïd C, Nunes H, Reynaud D, et al.
Cancers · 2023 · Journal Article
Grambow-Velilla J, Seban RD, Chouahnia K, Assié JB, et al.
La Revue du praticien · 2021 · Journal Article
Zelek L, Duchemann B
Lung cancer (Amsterdam, Netherlands) · 2025 · Journal Article
Pierret T, Greillier L, Guisier F, Daniel C, et al.
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
Abstract Background Immunotherapy represents a new therapeutic approach in non-small cell lung carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic nature and heterogeneity of tumoral dise
First-line immune-checkpoint inhibitor plus chemotherapy <i>versus</i> chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
Introduction:Platin-based chemotherapy (CT) has long been the first-line standard-of-care for patients with extensive-stage small-cell lung cancer (ES–SCLC). Adding immune-checkpoint inhibitor(s) to CT (ICI+CT) in this s
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
Background:Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently,
ICU admission for solid cancer patients treated with immune checkpoint inhibitors
Abstract Background Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to descri
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
Abstract Background Immunotherapy represents a new therapeutic approach in non-small cell lung carcinoma (NSCLC) with the potential for prolonged benefits. Because of the systemic nature and heterogeneity of tumoral dise
First-line immune-checkpoint inhibitor plus chemotherapy <i>versus</i> chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
Introduction:Platin-based chemotherapy (CT) has long been the first-line standard-of-care for patients with extensive-stage small-cell lung cancer (ES–SCLC). Adding immune-checkpoint inhibitor(s) to CT (ICI+CT) in this s
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).